Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Jan 8, 2016 at 11:25 AM EST

Ardelyx Gears Up for Secondary Offering

Ardelyx recently filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.

Lee Jackson | Jan 8, 2016 at 11:05 AM EST

Merrill Lynch Has 4 Safe Dividend-Paying Mega-Cap Pharmaceutical Stocks to Buy

One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap…

Chris Lange | Jan 8, 2016 at 10:35 AM EST

Collegium Pharmaceutical Prices Secondary Offering

Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.

Chris Lange | Jan 8, 2016 at 10:05 AM EST

Jaguar Animal Health Gears Up for Secondary Offering

Jaguar Animal Health has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.

Trey Thoelcke | Jan 8, 2016 at 7:20 AM EST

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny.…

Chris Lange | Jan 7, 2016 at 1:55 PM EST

Dynavax Soars on Positive Late Stage Results

Dynavax Technologies led the bulls on Thursday with positive results from a late stage clinical trial, on another consecutive down…

Chris Lange | Jan 6, 2016 at 11:35 AM EST

Visterra Readies for IPO

Visterra has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange | Jan 6, 2016 at 10:35 AM EST

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson

24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case…

Chris Lange | Jan 5, 2016 at 12:50 PM EST

Tabula Rasa HealthCare Takes First Step Toward IPO

The U.S. Securities and Exchange Commission (SEC) has received a filing from Tabula Rasa HealthCare regarding its initial public offering…

Chris Lange | Jan 5, 2016 at 12:35 PM EST

Exelixis Posts Positive Late Stage Results in METEOR trial

Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The…

Chris Lange | Jan 5, 2016 at 11:45 AM EST

Janney Weighs in on Acceleron Pharma

Janney Capital has weighed in on biotech company Acceleron Pharma and what its outlook stands to be for the future.

Chris Lange | Jan 5, 2016 at 11:35 AM EST

Mannkind Sinks on Afrezza License Termination

MannKind Corp. (NASDAQ: MNKD) is one of the most traded biotech companies on the market, and one of the most…

Chris Lange | Jan 5, 2016 at 11:20 AM EST

Akebia Plans to Raise Capital in Most Recent Proposed Offering

Akebia Therapeutics plans on raising capital, according to its most recent proposed public offering.

Chris Lange | Jan 4, 2016 at 12:40 PM EST

Bavarian Nordic Files for IPO

Bavarian Nordic has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Lee Jackson | Jan 4, 2016 at 10:05 AM EST

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as…

1 … 228 229 230 231 232 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Ardelyx Gears Up for Secondary Offering

Merrill Lynch Has 4 Safe Dividend-Paying Mega-Cap Pharmaceutical Stocks to Buy

Collegium Pharmaceutical Prices Secondary Offering

Jaguar Animal Health Gears Up for Secondary Offering

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

Dynavax Soars on Positive Late Stage Results

Visterra Readies for IPO

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson

Tabula Rasa HealthCare Takes First Step Toward IPO

Exelixis Posts Positive Late Stage Results in METEOR trial

Janney Weighs in on Acceleron Pharma

Mannkind Sinks on Afrezza License Termination

Akebia Plans to Raise Capital in Most Recent Proposed Offering

Bavarian Nordic Files for IPO

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

BofA Just Deemed Ulta Beauty a High-Quality Compounder. Time to Buy the 26% Pullback?

The IRA and 401(K) Tax Trap That Catches Retirees off Guard

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

Health and Healthcare Articles

All Health and Healthcare Articles

Ardelyx Gears Up for Secondary Offering

Merrill Lynch Has 4 Safe Dividend-Paying Mega-Cap Pharmaceutical Stocks to Buy

Collegium Pharmaceutical Prices Secondary Offering

Jaguar Animal Health Gears Up for Secondary Offering

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

Dynavax Soars on Positive Late Stage Results

Visterra Readies for IPO

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson

Tabula Rasa HealthCare Takes First Step Toward IPO

Exelixis Posts Positive Late Stage Results in METEOR trial

Janney Weighs in on Acceleron Pharma

Mannkind Sinks on Afrezza License Termination

Akebia Plans to Raise Capital in Most Recent Proposed Offering

Bavarian Nordic Files for IPO

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Pete Buttigieg’s 2024 antitrust win just erased 17,000 jobs and the largest U.S. ultra-low-cost ariline

Oil’s Decline Opens the Door on These 4 Sub-$30 Buys

BofA Just Deemed Ulta Beauty a High-Quality Compounder. Time to Buy the 26% Pullback?

Featured Reads

The IRA and 401(K) Tax Trap That Catches Retirees off Guard

Is College Still Worth It? Ron Lieber's Advice for Parents Navigating Shifting Job Market